SuperworthCencora EPS COR
Diluted earnings per share by quarter and over the last twelve months, from 2008.
- Last 12 months, to Jun 30, 2026
- $13.46
- Latest quarter, Q3 FY26
- $3.94
- +12% on a year earlier
- Fiscal year 2025
- $7.95
- +6% on the year before
Cencora's earnings per share was $13.46 over the twelve months to Jun 30, 2026, up 38% on a year earlier.
In its latest quarter, Q3 FY26, it was $3.94, up 12% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $7.95 | +6% |
| FY2024 | $7.51 | −12% |
| FY2023 | $8.53 | +6% |
| FY2022 | $8.04 | +9% |
| FY2021 | $7.39 | n/a |
| FY2020 | −$16.79 | −517% |
| FY2019 | $4.03 | −46% |
| FY2018 | $7.51 | +364% |
| FY2017 | $1.62 | −74% |
| FY2016 | $6.32 | n/a |
| FY2015 | −$0.79 | −345% |
| FY2014 | $0.32 | +77% |
| FY2013 | $0.18 | −35% |
| FY2012 | $0.28 | +10% |
| FY2011 | $0.25 | +14% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | $3.94 | +12% | $13.46 | |
| Q2 FY26 | $8.40 | +128% | $13.04 | |
| Q1 FY26 | $2.87 | +15% | $8.32 | |
| Q4 FY25 | −$1.75 | −8850% | $7.95 | |
| Q3 FY25 | $3.52 | +45% | $9.72 | |
| Q2 FY25 | $3.68 | +76% | $8.62 | |
| Q1 FY25 | $2.50 | −16% | $7.03 | |
| Q4 FY24 | $0.02 | −99% | $7.51 | |
| Q3 FY24 | $2.42 | +3% | $9.21 | |
| Q2 FY24 | $2.09 | −2% | $9.14 | |
| Q1 FY24 | $2.98 | +28% | $9.18 | |
| Q4 FY23 | $1.72 | +23% | $8.53 |
Against its peers
Companies in Medical - Distribution nearest Cencora's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CORCencora | $13.46 | +38% a year |
| CAHCardinal Health | $7.24 | +12% a year |
| MCKMcKesson | $37.35 | +49% a year |
| HSICHenry Schein | $3.43 | +10% a year |
| Peer median | $7.24 |
Where Cencora ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Cencora
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.